Althoughexperimentalevidence indicatesa probableroleof epidermalgrowthfactor receptor(EGFr) in clinicaloncology, no standardized method for its determinationhas been yet described, and discrepant results have been reported in clinical studies. In standardizing a radioligandbindingassay for EGFr, we evaluatedthe causes of variabilityin each step of the assay. Entrapmentof EGFr in the nuclearfractionand contamination of the crude membrane fraction by cytosol protein were eliminated through preliminary purification steps. Both Scatchard and Rosenthalanalysisof the saturation reaction of the membrane fractionwith a wide range of concentrationsof 1251-labeled EGF revealed a double class of bindingsites. Study of the saturation reaction showed a partial exchange of '251-labeledEGF with endogenousEGF within 20 h. The presentmethod-incubation of partly purified membranefraction with 1251-Iabeled EGF, 0.5 nmol/L, with and without 100-fold excess of cold EGF, for 20 h at 26#{176}C, followed by centnfugationat 5000 x g for 30 mm to separate membrane-bound1251-labeled EGF-shows good sensitivity, precision, and accuracy; is reasonably simple; and may be suitable for routineclinicaluse. Each research group using biochemical assays reported a different method (9-il, 16, 22-27), no standardized procedure being yet available. Reportedmethodsvary both in the assay procedure and in the procedure for preparing the tissue fraction in which EGFr is determined. Standardization of the method is therefore mandatory so that clinical studies from different centers can be compared.
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Addftlonal Keyphrases:hormone receptors -membrane and nuclearfractions . sample preparation variation, source of Epidermal growth factor (EGF), a 6000-Da single-chain polypeptide, plays a role in regulating the growth of ectodermal-derived cells (1). ' The biological actions of EGF are mediated by a specific cell-surface receptor, EGFr, a 170 000-Da glycoprotein with an extracellular domain that binds EGF and an intracellular domain that contains intrinsic tyrosine kinase activity (2, 3). The enzymatic activity is directed against several protein substrates and the receptor itself (4) (5) (6) .
Alterations of the EGF-EGFr interaction machinery have recently been shown to be related to malignant transformation. Indeed, a peptide isolated from cultures of malignant cells, transforming growth factor alpha (TGFa), stimulated the growth of malignant tissues by an autocrine mechanism through binding to the EGFr (7,8). Experimen Each research group using biochemical assays reported a different method (9-il, 16, 22-27) , no standardized procedure being yet available. Reportedmethodsvary both in the assay procedure and in the procedure for preparing the tissue fraction in which EGFr is determined. Standardization of the method is therefore mandatory so that clinical studies from different centers can be compared.
For the present study we wanted to set up a reproducible and accurate radioligand binding method for EGFr determination by investigating the causes of variability for each step of the assay.
MaterIals and Methods

Tissue Samples
Human term placentas collected fresh after delivery were, without delay, placed on ice. Ainnion and chorion were removed by dissection. Placental tissue was washed several times with cold isotonic saline solution (NaCl 150 mmol/L, 4#{176}C), minced, frozen, and stored in liquid nitrogen.
Reagents
Both native human EGF and 1251-labeled human EGF (specific activity 1100-1300 kCi/mol; radioactivity concentration 100 mCiJL; prepared by the lactoperoxidase method) were purchased from Amersham International (Cardifl U.K).
Human TGFa was purchased from Bio-Tope (Redmond, WA); porcine platelet-derived growth factor, bovine fibroblast growth factor, and human insulin-like growth factor I were purchased from Boehringer Mannheim (Mannheim, F.R.G.).
Tris . HC1, EDTA, sodium azide, MgC12, bovine serum albumin, and Triton X-100 were purchased from Sigma The pelleted crude nuclear fraction was resuspended in TENG buffer and repelleted twice more at 800 x g. Supernates were pooled and centrifuged at 100 000 X g for 1 h at 4#{176}C. The pellet was resuspended in TENGM buffer (TENG buffer containing MgCl2, 10 mmoIJL) at 1 g of tissue per 3 mL of buffer, then homogenized with use of a glass/Teflon tapered tissue grinder homogenizer (Wheaton Scientific, Millville, NJ) at 4#{176}C. The nuclear pellet (washed nuclear pellet) was further purified as follows: we centrifuged the pellet at 40 000 x g for 1 h over a 750 g/L sucrose cushion to remove any cell membrane fragment entrapped in the crude nuclear pellet (membrane-free nuclear pellet) (28) , then we resuspended the nuclear pellet in TENGM buffer, with Triton X-100 (10 mLIL) added, and centrifuged at 3000 x g for 10 mm, to solubilize any intact cell or tissue fragment and recover the nuclei (pure nuclear fraction). The pellets of both the membrane-free and the pure nuclear fractions were resuspended in TENG buffer (1 g/5 mL) and homogenized by using the glass/Teflon homogenizer.
Saturation assay. We assayed EGFr by the radioligand binding assay, using both the multipoint titration curve nmol/L. The sample was then centrifuged at 100 000 x g for 1 h, and the supernate containing free EGF was eliminated. The pellet was returned to its initial volume with TENGM buffer and homogenized with the glass/Teflon homogenizer.
To desaturate the receptor from the endogenous EGF, we incubated the sample at pH 4.2 (attained by mixing with acetate buffer, pH 3.6, 100 L of buffer per 1 mL of sample) for 3 mm at 26#{176}C (31), then tenninated this processby adding TENGM buffer, pH 7.4. After centrifuging the sample at 100000 x g for 1 h, we discarded the supernate and homogenized the pellet with enough TENGM buffer to return the sample to its initial volume.
1251..EGF boundifree separation. We separated the bound and free '25I-EGF by centrifugation for 30 mm at various g-forces (2500, 5000, 11 000, 16 000, and 50000 x g). We also evaluated the effect of adding polyethylene glycol 6000 (final concentration 100 g/L) in TNGB buffer and centrifuging at 5000 x g for 30 mm.
The results of EGF determinations after the different centrifugation conditions were expressed as the percent of the EGF bound to the receptors pelleted at 100 000 x g for 1 h, conditions that allow a complete recovery of the membrane fraction. 
Results
Preparationof the MembraneFraction
Treatment of the nuclear pellet. EGFr content was determined in the homogenate as well as in the membrane and the nuclear fractions (Table 1) . A large amount (76%) of the total cell content of EGFr was lost in the nuclear fraction.
The nuclear washing allows for a recovery of -53%, not significantly different (P >0.05) from the results obtained by centrifugation over a sucrose cushion.
Therefore, we conclude that nuclear washing before preparing the membrane fraction pellet allows an almost complete recovery of the plasma membrane disrupted through homogenization.
The treatment with Triton X-100 solubilizes completely the membrane of intact cells pelleted with nuclei, and allows the recovery of a pure nuclear fraction in which no EGFr is assayable (data not shown 
prepare the nuclei-free cellular fraction by centrifuging at 5000-10 000 x g to eliminate the nonmembrane protein contamination (mainly from the mitochondrial fraction) (24, 35) . We evaluated the EGFr content of the membrane fraction obtained with and without preliminary purification through centrifugation at 12000 x g. The EGFr concentration was significantly greater (P <0.01) in the crude membrane fraction than in the mitochondria-free fraction, when expressed in fmol/mL, and was approximately equal when expressed in fmollmg of protein of the fraction ( Table 2 #{176}The nuclei-freefractionwas centrifuged at 100000 x gfor 1 hand the pellet was assayed. "The nuclei-free fraction was centrifuged at 12000 x g for 15 mm, the pellet was washed twice, and the supematant liquid was centrifuged at 100 000 x g for 1 h before the assay of the resulting pellet that in the presence of concentrations of unlabeled EGF ranging from 50 to 2500 nmoIJL (equivalent to 100 to 5000 times the saturating concentration of 'I-EGF), the 'I-EGF binding decreases to about 10%, which represents the nonspecific binding. Therefore, (a) a 100-fold excess of unlabeled EGF is sufficient to saturate specific binding sites almost completely, and (b) it is apparently not necessary to dilute the unlabeled EGF in relation to 1251-EGF concentration used, a procedure previously suggested for steroid receptors (38) .
Temperature. We evaluated three different incubation temperatures. The greatest '251-EGF specific binding was obtained at 26#{176}C, irrespective of the incubation time, from 2 to 20 h (Table 4) 
Separation of Bound and Free 125l-EGF
Separation by centrifuging is the method of choice when several samples have to be processed.
However, low-speed centri.fugation allows only partial recovery of receptorbound 125I-EGF. We tested several centrifugation conditions, to compare the result for bound lmIEGF with the bound '251-EGF obtained by centrifuging at 100000 x g for 1 h. Figure 4 shows that, whereas nonspecific binding is not significantly affected by the centrifugation conditions, the specific binding increases as the centrifugal force is increasedto 100000 xg. 
PerformanceCharacteristicsof the Assay
The reproducibility of the assay was evaluated by using samples obtained from pooled placental membranes stored at -70 #{176}C. Results showed satisfactory precision characteristics, and the CV ranged from 4% to 8% (eight replicates,
within-assay)
and from 9.6% to 10.7% (10 replicates, be-
tween-assay).
To evaluate the assay sensitivity, we prepared several samples by serially diluting the placental membrane preparations and assayed them by Scatchard analysis. Sensitivity, defined as the lowest EGFr concentration measurable when the difference between total binding and nonspecific binding counts significantly exceeded the difference due to intra-assay variability, was 1.5 fmollmL.
To assess binding specificity, we evaluated the ability of several unlabeled ligands to displace issIEGF ( Figure 5 ). As expected, TGFa was effective in inhibiting 1251-EGF binding to the receptor, with 50% inhibition by TGFa at approximately 1 nmoi/L. Fibroblast growth factor, plateletderived growth factor, and insulin-like growth factor I were not able to displace 1I-EGF from its receptor at concentrations up to 500-fold that of EGF.
Accuracy was evaluated by using a dilution test. Specific binding increased linearly (y = -1 + 0.99x) up to a EGFr value equal to the final concentration of tracer used, independent of membrane protein concentrations as great as 0.1 mg/mL.
DIscussion
The study of the autocrine mechanism of control of cell growth is a topic of increasing interest in oncology (39, 40) . Finally, to separate receptor-bound from the free ligand, we chose a centrifl.igation procedure capable of a reproducible recovery of receptor. The alternative methods so far available (9-11, 23, 27 ) are too cumbersome and time consuming to be used routinely.
From the above findings we conclude that the described method takes into account several variables not previously considered, to our knowledge, in already published papers; presents good performance characteristics; and is reasonably simple and rapid enough to be used routinely in clinical trials. 
